Our data generate new hypotheses that CD155 appear to be the target of immunotherapy for the CD155-positive bladder cancer, CD155Bi-Ab-armed ATCs would provide a novel strategy for the immunotherapy of CD155-positive bladder cancer in the future. The gene discussed is PVR; the disease is urinary bladder carcinoma.